$8.460
-0.186 (-2.20%)收盤時
CPIX 資訊
CPIX 事件
Cumberland Authorizes Up to $5M Share Repurchase Program
In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5M in Cumberland shares over time. Several Board members will also be establishing new share purchase plans to increase their holdings in the Company.
Cumberland Pharmaceuticals Declares Special Cash Dividend of $1.50 per Share
Cumberland Pharmaceuticals Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock. The dividend will be payable on July 31, to the shareholders of record at the close of business on July 10.
Cumberland Pharmaceuticals Updates DMD Trial Results
Cumberland Pharmaceuticals shared updated results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy heart disease, at the annual Parent Project Muscular Dystrophy conference in Orlando, Florida. The presentation highlighted key updates to the primary findings in the FIGHT DMD trial, reinforcing ifetroban's potential to address the leading cause of death in patients with DMD. The 12-month Phase 2 FIGHT DMD trial previously demonstrated that high-dose ifetroban treatment resulted in a significant 5.4% improvement in left ventricular ejection fraction compared to a control group composed of placebo-treated patients combined with propensity score-matched natural history patients. The study findings also included reductions in cardiac damage markers in the high-dose group. All patients who completed the 12-month study opted to continue in the open-label extension. New findings from the Phase 2 FIGHT DMD trial, supported by long-term safety data from the ongoing open-label extension, further characterize the cardioprotective effect exerted by ifetroban in DMD cardiomyopathy. Through 36 months of treatment across both the Phase 2 trial and the open-label extension, ifetroban maintained a favorable safety profile in DMD patients with no treatment-related serious adverse events or new safety concerns. Evaluation of novel blood biomarkers identified a 30% reduction in MYL3 and a 50% reduction in MYOD1, alongside a 2.4-fold increase in FGF16 and a 2.1-fold increase in TSPAN7 with ifetroban treatment compared with placebo. These confirmatory findings further support the potential therapeutic mechanisms for ifetroban in DMD cardiomyopathy.
Cumberland Pharmaceuticals and Vanderbilt Health Announce Ifetroban Clinical Trial Data
Cumberland Pharmaceuticals and Vanderbilt Health announce data from a Phase 2a clinical trial of ifetroban to prevent metastasis in high-risk solid tumors. The study's primary safety endpoint was achieved, along with favorable trends in decreased metastasis recurrence and metastasis-free survival. A safe and effective medication that reduces distant metastatic recurrence could transform cancer management and improve the lives of millions of cancer survivors and their families. The randomized, double-blind, placebo-controlled Phase 2a trial evaluated the safety of ifetroban, an investigational thromboxane A2 receptor antagonist, in patients with solid tumors at high risk of early metastatic recurrence. Cancer types included breast, lung, pancreatic, soft tissue, bladder, and renal cancers. The study met its primary endpoint, demonstrating that ifetroban was safe and well-tolerated in this patient population. Rates for adverse events related to treatment were similar between placebo and ifetroban. No serious adverse events in either group were identified as being related to study treatment. Treatment discontinuation rates were not statistically different between placebo and ifetroban. Although primarily a safety study and intentionally not powered for efficacy, the study compared the percentage of patients with distant metastatic recurrence 12 months after completion of therapy in both groups (10 placebo-treated and 18 ifetroban-treated participants) as a prespecified secondary endpoint. While 50% of participants experienced distant metastatic recurrence in the placebo arm, only 17% of participants experienced distant metastatic recurrence in the ifetroban arm. Three deaths due to distant metastatic disease occurred in the placebo arm, and none occurred in the ifetroban arm.
Cumberland Launches Vibativ Injection in China
Cumberland announced the launch of its Vibativ - telavancin - injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals. The launch follows an agreement granting SciClone exclusive rights to register, promote and distribute telavancin, injection across China. The product's approval by China's National Medical Products Administration, or NMPA, enables SciClone to commercialize the product in one of the world's largest and fastest-growing pharmaceutical markets. Telavancin is a patented, FDA-approved injectable anti-infective that serves as a potentially life-saving treatment for patients with serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia. Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。